Popliteal arterial thrombosis in nephrotic syndrome: a case report

Tachamo, Niranjan; Dhital, Rashmi; Timilsina, Bidhya; Nazir, Salik; Lohani, Saroj; Poudel, Dilli Ram

doi:10.1080/20009666.2017.1286814

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arterial thrombosis appears to be less common than venous forms in NS, but does appear to be elevated nonetheless. 29 , 30 Whether DOACs have the ability to prevent stroke and myocardial infarction in NS as they do in patients with stable atherosclerotic vascular disease without NS is not yet known. 31 However, case reports of DOAC use in arterial thrombosis in NS are emerging ( Table 2 ).…”

Section: Casementioning

confidence: 99%

Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome

Sexton

Freitas

Little

et al. 2018

Kidney International Reports

View full text Add to dashboard Cite

We report 2 cases of apixaban use as prophylaxis against thromboembolism in the nephrotic syndrome (NS), and review the existing literature on direct-acting oral anticoagulant (DOAC) use in this scenario. Our cases appear to be the first reported use of apixaban as prophylaxis against thromboembolism in NS. We report our systematic review of the existing literature on direct-acting oral anticoagulant (DOAC) use in NS, and discuss theoretical issues relevant to their therapeutic use in this clinical scenario. We searched electronic databases such as OVID, EMBASE, PubMed, and CENTRAL, DARE. The search to identify studies and the application of inclusion and exclusion criteria was performed in duplicate independently. We identified 1 pilot randomized study, 3 case reports, and 3 conference proceedings abstracts relating to DOAC use in NS. These reports all pertain to the treatment of clinically evident thrombosis in NS with rivaroxaban, edoxaban, and dabigatran rather than prophylaxis against thrombosis. Although the existing literature on DOAC use in NS is limited, initial preliminary experience appears promising.

show abstract

Section: Casementioning

confidence: 99%

Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome

Sexton

Freitas

Little

et al. 2018

Kidney International Reports

View full text Add to dashboard Cite

show abstract

“…Venous thrombotic complications have frequently been observed (2). Arterial complications are rare and may lead to serious and life-threatening complications depending on the vessels involved and associated with poor prognosis (2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%